Relmada Therapeutics Inc (RLMD)
NASDAQ:RLMD
Want to see RLMD full AI Analyst Report?
RLMD Stock Chart & Stats
$7.48
-$0.01(-3.06%)
At close: 4:00 PM EST
$7.48
-$0.01(-3.06%)
Day’s Range― - ―
52-Week Range$0.52 - $8.00
Previous CloseN/A
Volume447.03K
Average Volume (3M)1.02M
Market Cap
$673.40M
Enterprise Value$518.96M
Total Cash (Recent Filing)$233.96M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.56
Next Earnings
Aug 11, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding104,890,220
10 Day Avg. Volume945,183
30 Day Avg. Volume1,017,673
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-4.16
Enterprise Value/Market Cap0.77
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-8.60
Forecast
1Y Price Target
$15.50Price Target Upside107.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessNDV-01 for high-grade non-muscle invasive bladder cancer showed an overall response rate of 85% and high-grade recurrence-free survival in patients with papillary disease of 83%.
Competitive AdvantageNDV-01's novel sustained-release formulation could have blockbuster potential due to its ease of administration and increased efficacy.
Market OpportunityThe in-licensing of NDV-01 for treating NMIBC represents a multi-billion opportunity for Relmada Therapeutics Inc.
Bears Say
Development Re-evaluationThe company is re-evaluating further development of ‘P11 (novel psilocybin) as part of its prioritization efforts.
Uncertain Financial OutlookThe company ended the year with $27M in cash, and additional data and updates from the pipeline are awaited before making any substantive comments regarding the pipeline assets.
Valuation ConcernsAt this point, the product is not being added into the valuation, and the recommendation remains Market Perform.
Relmada Therapeutics News
RLMD FAQ
What was Relmada Therapeutics Inc’s price range in the past 12 months?
Relmada Therapeutics Inc lowest stock price was $0.52 and its highest was $8.00 in the past 12 months.
What is Relmada Therapeutics Inc’s market cap?
Relmada Therapeutics Inc’s market cap is $673.40M.
When is Relmada Therapeutics Inc’s upcoming earnings report date?
Relmada Therapeutics Inc’s upcoming earnings report date is Aug 11, 2026 which is in 68 days.
How were Relmada Therapeutics Inc’s earnings last quarter?
Relmada Therapeutics Inc released its earnings results on May 12, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.2 by -$0.02.
Is Relmada Therapeutics Inc overvalued?
According to Wall Street analysts Relmada Therapeutics Inc’s price is currently Undervalued.
Does Relmada Therapeutics Inc pay dividends?
Relmada Therapeutics Inc does not currently pay dividends.
What is Relmada Therapeutics Inc’s EPS estimate?
Relmada Therapeutics Inc’s EPS estimate is -0.19.
How many shares outstanding does Relmada Therapeutics Inc have?
Relmada Therapeutics Inc has 104,890,220 shares outstanding.
What happened to Relmada Therapeutics Inc’s price movement after its last earnings report?
Relmada Therapeutics Inc reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.2. Following the earnings report the stock price went up 0.537%.
Which hedge fund is a major shareholder of Relmada Therapeutics Inc?
Currently, no hedge funds are holding shares in RLMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Relmada Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (107.22% Upside)
$15.50 (107.22% Upside)
Blogger Sentiment
Bullish
RLMD Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 3.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 4.1%
Last 30 Days ▼ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
806.77%
12-Months-Change
Fundamentals
Return on Equity
-71.22%
Trailing 12-Months
Asset Growth
750.32%
Trailing 12-Months
Company Description
Relmada Therapeutics Inc
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
RLMD Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: robust phase 2 12-month efficacy and safety data for NDV-01, FDA alignment for a two-pathway Phase 3 registrational program, strengthened IP positioning via a provisional patent filing, and a materially improved balance sheet with ~$234M cash (runway into 2029). Operational advantages (office-based, short administration) and a planned Cipranolone proof-of-concept add to the upside. Key challenges include a significant rise in G&A expense, a modestly larger absolute net loss, patent prosecution uncertainty, and potential variability in Phase 3 patient populations which could affect measured efficacy. Overall, the highlights substantially outweigh the lowlights, but successful execution of the planned mid-2026 trial starts and subsequent enrollment/readouts remain critical.View all RLMD earnings summariesRLMD Stock 12 Month Forecast
Average Price Target
$15.50
▲(107.22% Upside)
Technical Analysis
Ownership Overview
2.87% Insiders
3.74% Mutual Funds
47.67% Other Institutional Investors
42.10% Public Companies and
Individual Investors